From Grant to Growth: Financial Infrastructure Across the Life Sciences Funding Lifecycle

Life sciences companies are built on breakthrough ideas, but they are scaled through capital.

From early-stage grants to venture capital and strategic pharmaceutical partnerships, each phase of funding creates new opportunities and new financial complexities. While much of the industry’s focus is on science, innovation, and regulatory milestones, another critical factor often receives less attention: financial infrastructure.

The Idea Phase: Grants and Non-Dilutive Funding

For many life sciences companies, the journey begins with grants and non-dilutive funding sources such as NIH grants, SBIR programs, and foundation funding. At this stage, organizations are focused on validating scientific concepts and establishing early credibility.

While these funding sources do not dilute ownership, they introduce their own operational demands. Funding is often milestone-based, requiring companies to demonstrate progress before additional capital is released. In many cases, once funding crosses certain thresholds, formal audit requirements come into play.

What this means in practice is that even at the earliest stage, companies need more than basic bookkeeping. They need the ability to:

• Track expenditures by funding source
• Maintain audit-ready financial records
• Demonstrate compliance with grant requirements

This is where structured financial systems begin to matter. Platforms like Sage Intacct support multi-dimensional tracking, allowing organizations to monitor grants, projects, and departments in parallel without creating unnecessary complexity in the chart of accounts.

Companies that establish this level of visibility early are far better positioned to build credibility with future investors.

The Prototype Phase: Pre-Seed and Early Funding

As organizations move beyond the idea stage, they begin raising capital from angel investors, friends and family, and early-stage funds to develop prototypes and proof-of-concept products.

This is a pivotal transition. The organization is no longer just a research initiative, but it is also becoming an operating business.

At this stage, investors are still comfortable with high risk, but expectations begin to shift. Stakeholders want to understand:

• How quickly the company is burning cash
• Whether progress aligns with funding milestones
• What near-term financial trajectory looks like

Many companies attempt to manage this transition using spreadsheets or entry-level accounting systems. However, this often leads to inconsistent reporting, manual processes, and limited visibility into real-time performance.

This is typically where organizations begin to outgrow tools like QuickBooks—not necessarily due to transaction volume, but because of increasing complexity.

Cloud-based financial management platforms such as Sage Intacct enable real-time reporting, standardized financial processes, and scalable data structures, allowing leadership teams to manage growth with confidence rather than react to it.

The Growth Phase: Venture Capital and Institutional Investment

When companies reach the venture capital stage—Series A, B, and beyond—the stakes change significantly.

Investors are no longer funding potential; they are funding growth.

At this level, expectations expand to include:

• Clean, investor-ready financial statements
• Advanced reporting and KPIs (burn rate, runway, unit economics)
• Forecasting capabilities to support decision-making
• Increasing governance, including board reporting

Financial operations move from the back office to the center of the conversation. The ability to produce timely, accurate, and transparent reporting becomes a key factor in securing and maintaining investor confidence.

In many cases, organizations also introduce additional complexity such as multi-entity structures, expanded teams, and global considerations.

Sage Intacct is purpose-built to address these challenges, with capabilities such as:

• Multi-entity consolidation and reporting
• Role-based dashboards for executives and investors
• Automated financial close processes
• Real-time visibility into financial performance

At this stage, the finance function is no longer just accounting, it is a strategic asset that directly supports valuation and growth.

Strategic Partnerships and Big Pharma Collaboration

As life sciences companies mature, many begin exploring strategic partnerships with larger pharmaceutical organizations. These relationships can take many forms, including licensing agreements, joint development arrangements, or full acquisitions.

While these partnerships can be transformative, they introduce a new level of financial and operational complexity.

Companies must navigate:

• Revenue recognition tied to structured deal terms
• Co-development agreements and shared investment models
• Regulatory and compliance considerations
• Complex tax and audit implications

In addition, timing becomes a strategic factor, as large pharmaceutical companies often accelerate deal activity toward year-end based on budget availability and strategic priorities.

At this stage, financial systems must be capable of more than reporting historical activity. They must also support complex agreements and evolving business models.

Solutions like Sage Intacct provide advanced capabilities such as:

• Contract-based revenue recognition
• Support for multi-book accounting (e.g., GAAP vs. tax)
• Scalable reporting across entities, agreements, and geographies

These capabilities allow organizations to not only comply with requirements but also to confidently structure and manage strategic deals.

Beyond Funding: Financial Maturity as a Competitive Advantage

Each funding stage brings more than capital, it also brings new expectations, new risks, and new opportunities.

The organizations that successfully scale are those that recognize an important truth:

Funding readiness and financial readiness are not the same thing.

Companies that invest early in scalable financial infrastructure are better equipped to:

• Move quickly when funding opportunities arise
• Provide transparency to investors and stakeholders
• Navigate regulatory and audit requirements
• Support complex partnerships and deal structures

In contrast, companies that delay these investments often find themselves reacting to pressure rather than leading through it.

Ready for Your Next Funding Stage?

Whether you’re navigating grant compliance, preparing for your first institutional investment, or structuring a strategic partnership, your financial infrastructure should evolve in lockstep with your growth strategy.

At Dean Dorton, we help life sciences companies assess where they are today, and what they’ll need tomorrow and across their funding lifecycle. From financial system strategy and Sage Intacct implementation to audit readiness and advisory support, our team works alongside you to build the foundation necessary for sustained growth.

If you’re planning for a funding event, or simply want to ensure your financial operations are ready when the opportunity arises—let’s start the conversation.